Loading...
•
Jun 30, 2022
Intra-Cellular Q2 2022 Earnings Report
Intra-Cellular Therapies reported financial results for Q2 2022, highlighted by a significant increase in CAPLYTA revenue and advancements in development programs.
Key Takeaways
Intra-Cellular Therapies reported a total revenue of $55.6 million for the second quarter of 2022, a 178% increase compared to the same period in 2021. CAPLYTA net product revenues were $55.1 million, representing a 190% increase year-over-year. The company's net loss for the quarter was $86.6 million.
Total revenues for Q2 2022 were $55.6 million, compared to $20.0 million for Q2 2021, a 178% increase.
CAPLYTA net product revenues for Q2 2022 were $55.1 million, a 190% increase over Q2 2021.
CAPLYTA new and total prescriptions increased 225% and 191%, respectively, versus the same period in 2021.
Cash, cash equivalents, restricted cash and investment securities totaled $679.2 million at June 30, 2022.
Forward Guidance
The company expects to continue to deliver strong revenue growth throughout 2022 and looks forward to advancing their development programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...